Demographic and disease related characteristics of participants.

<p>Demographic and disease related characteristics of participants.</p

Distribution of compliance among all enrolled participants in the NL (n = 304-black) and NAM (n = 649-white) study cohorts.

<p>Distribution of compliance among all enrolled participants in the NL (n = 304-black) and NAM (n = 649-white) study cohorts.</p

(a) Fox Wearable Companion app main screen; (b) Fox Wearable Companion app activity graph; (c) Fox Wearable Companion app movement during sleep graph; (d) Fox Wearable Companion app symptom self-reports.

<p>“Reprinted from [Intel and Michael J Fox Foundation] under a CC BY license, with permission from [INTEL^®], original copyright [2017].</p

Distribution of data-contributors’ characteristics and influence on compliance for the NL and NAM cohorts.

<p>Distribution of data-contributors’ characteristics and influence on compliance for the NL and NAM cohorts.</p

Attrition in compliance per day for NL (n = 291, black) and NAM participants (n = 514, gray) during the follow up period.

<p>Attrition in compliance per day for NL (n = 291, black) and NAM participants (n = 514, gray) during the follow up period.</p

Number of participants actively collecting sensor data at the NL (gray) and NAM (black) cohorts during and after the follow-up period (total initial n = 805).

<p>Number of participants actively collecting sensor data at the NL (gray) and NAM (black) cohorts during and after the follow-up period (total initial n = 805).</p

SUS scoring of the Fox Wearable Companion platform (smartwatch with smartphone app) as rated by participants.

<p>SUS scoring of the Fox Wearable Companion platform (smartwatch with smartphone app) as rated by participants.</p

sj-docx-1-tan-10.1177_17562864241243186 – Supplemental material for Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Supplemental material, sj-docx-1-tan-10.1177_17562864241243186 for Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study by James F. Howard, Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J. Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Richard J. Nowak, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D. Weiss, Małgorzata Zajda, Jos Bloemers, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W. Duda, Mark Vanderkelen and M. Isabel Leite in Therapeutic Advances in Neurological Disorders</p